277 related articles for article (PubMed ID: 28052556)
1. Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases.
Carden MA; Smith S; Meany H; Yin H; Alazraki A; Rapkin LB
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28052556
[TBL] [Abstract][Full Text] [Related]
2. Significant responses to platinum-based chemotherapy in renal medullary carcinoma.
Strouse JJ; Spevak M; Mack AK; Arceci RJ; Small D; Loeb DM
Pediatr Blood Cancer; 2005 Apr; 44(4):407-11. PubMed ID: 15602719
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy With Bortezomib in Renal Medullary Carcinoma: A Case Series.
Ryan A; Tawagi K; VanderVeen N; Matrana M; Vasquez R
Clin Genitourin Cancer; 2021 Dec; 19(6):e395-e400. PubMed ID: 34565708
[TBL] [Abstract][Full Text] [Related]
4. Response to paclitaxel, gemcitabine, and cisplatin in renal medullary carcinoma.
Bell MD
Pediatr Blood Cancer; 2006 Aug; 47(2):228. PubMed ID: 16514612
[No Abstract] [Full Text] [Related]
5. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.
Walsh A; Kelly DR; Vaid YN; Hilliard LM; Friedman GK
Pediatr Blood Cancer; 2010 Dec; 55(6):1217-20. PubMed ID: 20979179
[TBL] [Abstract][Full Text] [Related]
6. [Renal medullary carcinoma: remission with gemcitabine-cisplatin and review of therapeutic perspectives].
Diao B; Paule B; Esquivel S; Abbou CC; Salomon L; De La Taille A
Prog Urol; 2010 Jul; 20(7):538-41. PubMed ID: 20656278
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).
Thibault C; Fléchon A; Albiges L; Joly C; Barthelemy P; Gross-Goupil M; Chevreau C; Coquan E; Rolland F; Laguerre B; Gravis G; Pécuchet N; Elaidi RT; Timsit MO; Brihoum M; Auclin E; de Reyniès A; Allory Y; Oudard S
Eur J Cancer; 2023 Jun; 186():83-90. PubMed ID: 37054556
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma.
Wilson NR; Wiele AJ; Surasi DS; Rao P; Sircar K; Tamboli P; Shah AY; Genovese G; Karam JA; Wood CG; Tannir NM; Msaouel P
Clin Genitourin Cancer; 2021 Dec; 19(6):e401-e408. PubMed ID: 34625389
[TBL] [Abstract][Full Text] [Related]
9. Cystic presentation of a renal medullary carcinoma in a young woman.
Levi Sandri GB; Spoletini G; Lai Q; Mennini G; Rossi M
Urologia; 2015; 82(2):124-6. PubMed ID: 25451881
[TBL] [Abstract][Full Text] [Related]
10. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.
Pécuchet N; Bigot F; Gachet J; Massard C; Albiges L; Teghom C; Allory Y; Méjean A; Escudier B; Oudard S
Ann Oncol; 2013 Dec; 24(12):2963-7. PubMed ID: 24190963
[TBL] [Abstract][Full Text] [Related]
11. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.
Wei D; Yang Y; Ricketts CJ; Vocke CD; Ball MW; Sourbier C; Wangsa D; Wangsa D; Guha R; Zhang X; Wilson K; Chen L; Meltzer PS; Ried T; Thomas CJ; Merino MJ; Linehan WM
Genes Chromosomes Cancer; 2020 Aug; 59(8):472-483. PubMed ID: 32259323
[TBL] [Abstract][Full Text] [Related]
12. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S
Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909
[TBL] [Abstract][Full Text] [Related]
13. Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases.
Peyromaure M; Thiounn N; Scotté F; Vieillefond A; Debré B; Oudard S
J Urol; 2003 Oct; 170(4 Pt 1):1138-40. PubMed ID: 14501710
[TBL] [Abstract][Full Text] [Related]
14. Renal medullary carcinoma: case report and review of the literature.
Noguera-Irizarry WG; Hibshoosh H; Papadopoulos KP
Am J Clin Oncol; 2003 Oct; 26(5):489-92. PubMed ID: 14528077
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
16. Response of metastatic renal medullary carcinoma to carboplatinum and Paclitaxel chemotherapy.
Gangireddy Vg; Liles GB; Sostre GD; Coleman T
Clin Genitourin Cancer; 2012 Jun; 10(2):134-9. PubMed ID: 22409864
[No Abstract] [Full Text] [Related]
17. Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study.
Sheng X; Cao D; Yuan J; Zhou F; Wei Q; Xie X; Cui C; Chi Z; Si L; Li S; Mao L; Lian B; Tang B; Yan X; Wang X; Kong Y; Dai J; Bai X; Zhou L; Guo J
Eur J Cancer; 2018 Sep; 100():1-7. PubMed ID: 29933095
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression.
Lipkin JS; Rizvi SM; Gatalica Z; Sarwani NE; Holder SL; Kaag M; Drabick JJ; Joshi M
Cancer Biol Ther; 2015; 16(1):28-33. PubMed ID: 25692619
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
Hu XC; Zhang J; Xu BH; Cai L; Ragaz J; Wang ZH; Wang BY; Teng YE; Tong ZS; Pan YY; Yin YM; Wu CP; Jiang ZF; Wang XJ; Lou GY; Liu DG; Feng JF; Luo JF; Sun K; Gu YJ; Wu J; Shao ZM
Lancet Oncol; 2015 Apr; 16(4):436-46. PubMed ID: 25795409
[TBL] [Abstract][Full Text] [Related]
20. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.
Shah AY; Karam JA; Malouf GG; Rao P; Lim ZD; Jonasch E; Xiao L; Gao J; Vaishampayan UN; Heng DY; Plimack ER; Guancial EA; Fung C; Lowas SR; Tamboli P; Sircar K; Matin SF; Kimryn Rathmell W; Wood CG; Tannir NM
BJU Int; 2017 Dec; 120(6):782-792. PubMed ID: 27860149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
